Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Jubilant Life Sciences 1Q12 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Jubilant Life Sciences 1Q12

CMO, Discovery/Development revenues rise

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Jubilant Life Sciences 1Q12

1Q Revenues: $209 million (+16%)

1Q Earnings: $17 million (+53%)

Comments: CMO revenues accounted for 16% of total revenues ($33 million), while Drug Discovery and Development Services accounted for 5% ($11 million). Life Science Products accounted for 78% of 1Q sales ($163 million), up 19% from the previous year, driven by volume growth and higher pricing. Generic revenues (part of Life Science Products) were up 33% to $29 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics